Blood biomarkers
Plasma alpha-synuclein, neurofilament light and other circulating markers under evaluation.
State of the art
No update yet for Blood biomarkers. An update is a standalone state-of-the-art for the topic — what someone with Parkinson's needs to know about where this approach stands today.
-
With new FDA green light for developer, Parkinson’s clinical trial to launch soon
In Parkinson's patients on GT-02287, blood levels of glucosylsphingosine (GluSph), a marker of impaired GCase activity, dropped by an average of 81% among those with elevated baseline levels; mouse studies also showed reduced neurofilament light, a marker of nerve damage. -
Prebiotics balance gut bacteria and show results in Parkinson’s blood
Researchers identified a 16-protein signature in blood-derived extracellular vesicles — tiny particles that cross the gut-brain barrier — that could distinguish Parkinson's patients from healthy adults and correlate with disease severity, offering a potential noninvasive method to monitor gut-targeted therapies; findings require validation in larger cohorts.